Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 9/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31643631 | 1.00 | CLK1 (0.53) | CLK1DYRK1AMAPK10LMNACYP3A4 | |
| SCHEMBL13859942 | 0.85 | CLK1 (0.44) | CLK1DYRK1AMAPK10LMNACYP3A4 | |
| SCHEMBL17917463 | 0.84 | IMPDH2 (0.43) | CLK1DYRK1AMAPK10LMNACYP3A4 | |
| SCHEMBL18099781 | 0.77 | KDM4E (0.57) | CLK1DYRK1AMAPK10LMNACYP3A4 | |
| SCHEMBL29568934 | 0.76 | LMNA (0.58) | CLK1DYRK1AMAPK10LMNACYP3A4 | |
| SCHEMBL1419171 | 0.76 | LMNA (0.58) | CLK1DYRK1AMAPK10LMNACYP3A4 | |
| SCHEMBL31398339 | 0.75 | CYP3A4 (0.61) | LMNACYP3A4KDM4EPOLBALDH1A1 | |
| SCHEMBL730579 | 0.75 | CYP3A4 (0.61) | LMNACYP3A4KDM4EPOLBALDH1A1 | |
| SCHEMBL672509 | 0.75 | CLK1 (0.54) | CLK1DYRK1AMAPK10LMNACYP3A4 | |
| SCHEMBL29569821 | 0.75 | CLK1 (0.54) | CLK1DYRK1AMAPK10LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130859-A1 | PALATABLE FORMULATIONS | ELANCO US INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | claimed |
| US-12544336-B2 | Palatable formulations | ELANCO US INC. | 2026-02-10 | — | — | US | claimed |
| US-20230372249-A1 | PALATABLE FORMULATIONS | ELANCO US INC. | 2023-11-23 | — | — | US | claimed |
| CN-116744917-A | Palatable formulations | 礼蓝美国公司 | 2023-09-12 | — | — | CN | claimed |
| EP-4208157-A1 | PALATABLE FORMULATIONS | ELANCO US INC. (US) | 2023-07-12 | — | — | EP | claimed |
| WO-2022051478-A1 | PALATABLE FORMULATIONS | ELANCO US INC. (US) | 2022-03-10 | — | — | WO | claimed |
| US-20120255502-A1 | PACKAGE AND METHOD OF MARKETING | ALLEVA ANIMAL HEALTH LIMITED (NZ) | 2012-10-11 | — | — | US | claimed |
| US-7550464-B2 | Use of phosphodiesterase 4 inhibitors such as 8,9-dimethoxy-6-phenyl-1,3,4,6,11,11a-hexahydro-2H -pyrazino[1,2-b]isoquinoline for treating asthma, chronic obstructive pulmonary disease, atopic dermatitis, allergic rhinitis, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis | MITSUBISHI TANBE PHARMA CORPORATION (JP) | 2009-06-23 | — | — | US | claimed |
| EP-1424326-B1 | FUSED-POLYCYCLIC COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-05-28 | — | — | EP | claimed |
| US-20070010521-A1 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. | 2007-01-11 | — | — | US | claimed |
| US-7153859-B2 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2006-12-26 | — | — | US | claimed |
| US-20040204418-A1 | Fused-polycyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2004-10-14 | — | — | US | claimed |
| EP-1424326-A1 | FUSED-POLYCYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2004-06-02 | — | — | EP | claimed |
| US-20260130859-A1 | PALATABLE FORMULATIONS | ELANCO US INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260130859-A1 | PALATABLE FORMULATIONS | ELANCO US INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-4162319-A | ANTHELMINTICS, PSYCHOTROPIC, CNS, HYPOGLYCOMIC AGENTS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1979-07-24 | — | — | US | disclosed |
| US-4120961-A | ANTIHELMINTICS, CNS ACITVITY | E. MERCK (DE) | 1978-10-17 | — | — | US | disclosed |
| US-3993760-A | 2-BENZOYL-4-OXO-1,2,3,6,7,11B-HEXAHYDRO-4H-PYRAZINO(2,1 -A)ISOQUINOLINE ISOMER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130859-A1 | PALATABLE FORMULATIONS | CYP3A7, PGC, THPO | CLK1 384/4885DYRK1A 1692/4885MAPK10 4438/4885 |
| US-20230372249-A1 | PALATABLE FORMULATIONS | THPO, APRT, PDE8A | CLK1 3934/4885DYRK1A 3714/4885MAPK10 4209/4885 |
| US-20070010521-A1 | Condensed polycyclic compounds | PDE4A, PDE4B, PDE3B | CLK1 3526/4885DYRK1A 4658/4885MAPK10 1138/4885 |
| US-12544336-B2 | Palatable formulations | TRHDE, TMPO, PGC | CLK1 1257/4885DYRK1A 2064/4885MAPK10 3675/4885 |
| US-20040204418-A1 | Fused-polycyclic compounds | PDE4A, PDE4B, PDE3B | CLK1 3634/4885DYRK1A 4482/4885MAPK10 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.